Yu-Shan HuangChien-Yu ChengHsin-Yun SunShu-Hsing ChengPo-Liang LuChen-Hsiang LeeYuan-Ti LeeHung-Chin TsaiChia-Jui YangChun-Eng LiuBo-Huang LiouShih-Ping LinSung-Hsi HuangMao-Wang HoHung-Jen TangChien-Ching HungYuan Pin Hung2026-02-032026-02-032023-06-1510.1128/spectrum.05125-22https://scholars.csmu.edu.tw/handle/123456789/4714<jats:p>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as a maintenance therapy showed durable and high rates of viral suppression for HIV/HBV-coinfected patients, with only 5.1% and 2.2% of patients having HBV DNA of ≥20 IU/mL and HIV RNA of ≥50 copies/mL, respectively, at 96 weeks. Our study fills the data gap on the long-term clinical effectiveness of tenofovir alafenamide-containing antiretroviral therapy in people living with HIV who have HBV coinfection.</jats:p>[SDGs]SDG3Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patientsjournal-article